Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 9,283 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Andecaliximab, Placebo to match Andecaliximab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 1 more
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT04106492
Conditions
Cancer
Interventions
SQ3370
Drug
Lead sponsor
Shasqi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Santa Monica, California + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

Lesinurad Tablet Bioequivalence

NCT02127775
Conditions
Healthy
Interventions
Lesinurad 400 mg (manufactured at Site 1), Lesinurad 400 mg (manufactured at Site 2)
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Austin, Texas
Conditions
Infections, Papillomavirus
Interventions
Cervarix™, Havrix™-based investigational formulation
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years · Female only
Enrollment
18,729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
50
States / cities
Birmingham, Alabama • Fountain Valley, California • San Diego, California + 39 more
Conditions
Locally Advanced or Metastatic Pancreatic Cancer
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
7
States / cities
Stanford, California • Lebanon, New Hampshire • Cleveland, Ohio + 4 more
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Conditions
SARS-CoV, SARS-CoV-2
Interventions
VXCO-100
Biological
Lead sponsor
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Decatur, Georgia • Baltimore, Maryland • Rochester, New York
Active, not recruiting Early Phase 1 Interventional

Niraparib In Recurrent IDH 1/2 Gliomas

NCT05406700
Conditions
Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
Interventions
Niraparib, Resection/Treatment with Niraparib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Healthy Volunteers
Interventions
PF-03882845 or Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Conditions
Healthy Volunteer
Interventions
ACHN-975, placebo
Drug
Lead sponsor
Achaogen, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Irritable Bowel Syndrome
Interventions
250 mg capsule, 250 mg tablets
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Relapsed/Refractory Small Cell Lung Cancer
Interventions
BMS-986525, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Detroit, Michigan • Buffalo, New York • Durham, North Carolina + 2 more
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
XmAb5574
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Augusta, Georgia • Columbus, Ohio • Nashville, Tennessee
Conditions
Prostatic Neoplasms
Interventions
JNJ-78278343
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
New York, New York • Seattle, Washington
Conditions
Advanced Solid Tumor
Interventions
DS-1103a, T-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
5
States / cities
Sarasota, Florida • New York, New York • Providence, Rhode Island + 2 more
Conditions
Cancer, Neoplasm
Interventions
SAR444881, Pembrolizumab, Cetuximab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
9
States / cities
Phoenix, Arizona • Duarte, California • Aurora, Colorado + 6 more
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (cellcept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Healthy Volunteer
Interventions
Test formulation (Treatment A), Reference formulation (Treatment B), Test formulation (Treatment C), Test formulation (Treatment D)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Neoplasms, Lymphoma, Hematologic Neoplasms
Interventions
TAK-981
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • Detroit, Michigan + 5 more
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
EPI-321
Biological
Lead sponsor
Epicrispr Biotechnologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
Conditions
Tumors
Interventions
BSI-201 (iniparib), irinotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-368, ABBV-181
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
La Jolla, California • Sacramento, California • Stanford, California + 7 more
Conditions
Major Depressive Disorder
Interventions
SHX-001 Active low dose, Placebo, SHX-001 Active High dose
Drug
Lead sponsor
Shenox Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio